TY - CHAP M1 - Book, Section TI - Treatment of High LDL Cholesterol A1 - Blaha, Michael J. A2 - Papadakis, Maxine A. A2 - McPhee, Stephen J. A2 - Rabow, Michael W. A2 - McQuaid, Kenneth R. PY - 2023 T2 - Current Medical Diagnosis & Treatment 2023 AB - Key Clinical Updates in Hyperthyroidism (Thyrotoxicosis)The FDA approved the novel PCSK9 inhibitor inclisiran, which uses silencing RNA technology to reduce liver production of PCSK9 protein by approximately 80%. Twice-yearly dosing is novel for lipid-lowering therapy; inclisiran enables new delivery strategies, including in-clinic administration.Raal FJ et al; ORION-9 Investigators. N Engl J Med. [PMID: 32197277]Ray KK et al; ORION-10 and ORION-11 Investigators. N Engl J Med. [PMID: 32187462] SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/28 UR - accessmedicine.mhmedical.com/content.aspx?aid=1193133499 ER -